<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887534</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_14_01</org_study_id>
    <nct_id>NCT02887534</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain</brief_title>
  <official_title>A Randomized, Double-blind, Active and Placebo-controlled, Study of SPARC1401 in Subjects With Moderate to Severe Acute Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 randomized clinical trial to evaluate efficacy and safety of SPARC1401 at three
      dose levels in patients with acute low back pain
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Anticipated">November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rating for medication helpfulness on five point scale: 0 - poor, 1 - fair, 2 - good, 3 - very good, 4 - excellent</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rating for medication helpfulness on five point scale: 0 - poor, 1 - fair, 2 - good, 3 - very, 4 - excellent</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Muscle Pain</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three times medication; SPARC1401-low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three times medication; SPARC1401-mid dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three times medication; SPARC1401-high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference1401; To be administered 3 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo1401 - 3 three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1401-low dose</intervention_name>
    <description>SPARC1401- low dose</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Test 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1401-mid dose</intervention_name>
    <description>SPARC1401- mid dose</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Test 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1401-high dose</intervention_name>
    <description>SPARC1401-high dose</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Test 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference1401 (Tizanidine)</intervention_name>
    <description>Reference1401 (Tizanidine) three times a day</description>
    <arm_group_label>Active comparator</arm_group_label>
    <other_name>Reference1401</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo1401</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <other_name>Placebo intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gives informed and written consent and is able to comply with all study assessments
             scheduled in the protocol

          -  Males or females aged 18 to 80 years (inclusive).

          -  Female subjects should be surgically sterile (bilateral tubal ligation at least 6
             months prior to randomization, bilateral oophorectomy or hysterectomy performed) or if
             they are of child-bearing potential, should be willing to practice an acceptable
             method of birth control from screening to completion of study.

          -  Subjects will be considered eligible for this trial based on medical evaluation,
             electrocardiogram and laboratory values at screening, and laboratory values outside
             normal range considered of no clinical significance by the investigator

        Exclusion Criteria:

          -  History or presence of clinically significant or uncontrolled cardiovascular,
             respiratory, neurological, psychiatric, hepatic, renal, gastrointestinal,
             hematological, or sleep disorder

          -  History or clinical signs or symptoms suggestive of stenosing peptic ulcer,
             pyloroduodenal obstruction, or inflammatory bowel disease

          -  History of diagnosis of cancer within 5 years prior to screening

          -  History of narrow-angle glaucoma, symptomatic prostatic hypertrophy, or bladder-neck
             obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tizanidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

